652 related articles for article (PubMed ID: 30099447)
21. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
22. CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.
Yang C; Boyson CA; Di Liberto M; Huang X; Hannah J; Dorn DC; Moore MA; Chen-Kiang S; Zhou P
Cancer Res; 2015 May; 75(9):1838-45. PubMed ID: 25744718
[TBL] [Abstract][Full Text] [Related]
23. T315 Decreases Acute Myeloid Leukemia Cell Viability through a Combination of Apoptosis Induction and Autophagic Cell Death.
Chiu CF; Weng JR; Jadhav A; Wu CY; Sargeant AM; Bai LY
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27537872
[TBL] [Abstract][Full Text] [Related]
24. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia.
Konopleva M; Tsao T; Ruvolo P; Stiouf I; Estrov Z; Leysath CE; Zhao S; Harris D; Chang S; Jackson CE; Munsell M; Suh N; Gribble G; Honda T; May WS; Sporn MB; Andreeff M
Blood; 2002 Jan; 99(1):326-35. PubMed ID: 11756188
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
[TBL] [Abstract][Full Text] [Related]
26. Gallic acid targets acute myeloid leukemia via Akt/mTOR-dependent mitochondrial respiration inhibition.
Gu R; Zhang M; Meng H; Xu D; Xie Y
Biomed Pharmacother; 2018 Sep; 105():491-497. PubMed ID: 29883944
[TBL] [Abstract][Full Text] [Related]
27. The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.
Allegretti M; Ricciardi MR; Licchetta R; Mirabilii S; Orecchioni S; Reggiani F; Talarico G; Foà R; Bertolini F; Amadori S; Torrisi MR; Tafuri A
Sci Rep; 2015 Dec; 5():18137. PubMed ID: 26674543
[TBL] [Abstract][Full Text] [Related]
28. Autophagy is an important event for low-dose cytarabine treatment in acute myeloid leukemia cells.
Chen L; Guo P; Zhang Y; Li X; Jia P; Tong J; Li J
Leuk Res; 2017 Sep; 60():44-52. PubMed ID: 28651104
[TBL] [Abstract][Full Text] [Related]
29. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells.
Xu L; Zhang Y; Gao M; Wang G; Fu Y
Biochem Biophys Res Commun; 2016 Apr; 472(4):662-8. PubMed ID: 26920060
[TBL] [Abstract][Full Text] [Related]
30. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
31. Emodin enhances ATRA-induced differentiation and induces apoptosis in acute myeloid leukemia cells.
Chen Y; Li J; Hu J; Zheng J; Zheng Z; Liu T; Lin Z; Lin M
Int J Oncol; 2014 Nov; 45(5):2076-84. PubMed ID: 25174432
[TBL] [Abstract][Full Text] [Related]
32. Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine.
Janus A; Linke A; Cebula B; Robak T; Smolewski P
Anticancer Drugs; 2009 Sep; 20(8):693-701. PubMed ID: 19584709
[TBL] [Abstract][Full Text] [Related]
33. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.
Fialin C; Larrue C; Vergez F; Sarry JE; Bertoli S; Mansat-De Mas V; Demur C; Delabesse E; Payrastre B; Manenti S; Roche S; Récher C
Leukemia; 2013 Feb; 27(2):325-35. PubMed ID: 22902361
[TBL] [Abstract][Full Text] [Related]
34. MK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.
Lu JW; Lin YM; Lai YL; Chen CY; Hu CY; Tien HF; Ou DL; Lin LI
Med Oncol; 2015 Jul; 32(7):206. PubMed ID: 26087957
[TBL] [Abstract][Full Text] [Related]
35. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
Chiarini F; Lonetti A; Teti G; Orsini E; Bressanin D; Cappellini A; Ricci F; Tazzari PL; Ognibene A; Falconi M; Pagliaro P; Iacobucci I; Martinelli G; Amadori S; McCubrey JA; Martelli AM
Oncotarget; 2012 Dec; 3(12):1615-28. PubMed ID: 23271044
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
37. The protein kinase C agonist prostratin induces differentiation of human myeloid leukemia cells and enhances cellular differentiation by chemotherapeutic agents.
Shen X; Xiong GL; Jing Y; Xiao H; Cui Y; Zhang YF; Shan YJ; Xing S; Yang M; Liu XL; Dong B; Wang LS; Luo QL; Yu ZY; Cong YW
Cancer Lett; 2015 Jan; 356(2 Pt B):686-96. PubMed ID: 25449427
[TBL] [Abstract][Full Text] [Related]
38. Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia.
Khoury H; He R; Schimmer A; Beadle JR; Hostetler KY; Minden MD
Chemotherapy; 2018; 63(4):225-237. PubMed ID: 30372692
[TBL] [Abstract][Full Text] [Related]
39. Emodin-induced autophagy against cell apoptosis through the PI3K/AKT/mTOR pathway in human hepatocytes.
Zheng XY; Yang SM; Zhang R; Wang SM; Li GB; Zhou SW
Drug Des Devel Ther; 2019; 13():3171-3180. PubMed ID: 31564833
[TBL] [Abstract][Full Text] [Related]
40. Emodin induces hepatocellular carcinoma cell apoptosis through MAPK and PI3K/AKT signaling pathways in vitro and in vivo.
Lin W; Zhong M; Yin H; Chen Y; Cao Q; Wang C; Ling C
Oncol Rep; 2016 Aug; 36(2):961-7. PubMed ID: 27278720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
